We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer.
- Authors
Zhang, Zhiying; Zhang, Rui; Li, Donghai
- Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that is conventionally characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), accounting for approximately 15– 20% of all breast cancers. Compared to other molecular phenotypes, TNBC is typically associated with high malignancy and poor prognosis. Cytotoxic agents have been the mainstay of treatment for the past few decades due to the lack of definitive targets and limited therapeutic interventions. However, recent developments have demonstrated that TNBC has peculiar molecular classifications and biomarkers, which provide the possibility of evolving treatment from basic cytotoxic chemotherapy to an expanding domain of targeted therapies. This review presents a framework for understanding the current clinical experience surrounding molecular biology mechanisms in TNBC (Figure 1). Including immunotherapy, polymerase (PARP) and PI3K/AKT pathway inhibitors, antibody-drug conjugates, and androgen receptor (AR) blockade. Additionally, the role of miRNA therapeutics targeting TNBC and potential strategies targeting cancer stem cells (CSCs) are discussed and highlighted. As more and more treatments arise on the horizon, we believe that patients with TNBC will have a new sense of hope.
- Subjects
TRIPLE-negative breast cancer; MOLECULAR biology; ANDROGEN receptors; EPIDERMAL growth factor; CANCER stem cells
- Publication
Biologics: Targets & Therapy, 2023, Vol 17, p113
- ISSN
1177-5475
- Publication type
Article
- DOI
10.2147/BTT.S426392